T
Tomasz Demkow
Researcher at Georgetown University
Publications - 65
Citations - 7735
Tomasz Demkow is an academic researcher from Georgetown University. The author has contributed to research in topics: Cancer & Sorafenib. The author has an hindex of 19, co-authored 63 publications receiving 7353 citations. Previous affiliations of Tomasz Demkow include Institut Gustave Roussy.
Papers
More filters
Journal ArticleDOI
Sorafenib in advanced clear-cell renal-cell carcinoma.
Bernard Escudier,Tim Eisen,Walter M. Stadler,Cezary Szczylik,Stéphane Oudard,Michael Siebels,Sylvie Negrier,Christine Chevreau,Ewa Solska,Apurva A. Desai,Frederic Rolland,Tomasz Demkow,Thomas E. Hutson,Martin Gore,Scott Freeman,Brian Schwartz,M. Shan,Ronit Simantov,Ronald M. Bukowski +18 more
TL;DR: As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects.
Journal ArticleDOI
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier,Tim Eisen,Walter M. Stadler,Cezary Szczylik,Stéphane Oudard,Michael Staehler,Sylvie Negrier,Christine Chevreau,Apurva A. Desai,Frederic Rolland,Tomasz Demkow,Thomas E. Hutson,Martin Gore,Sibyl Anderson,Gloria Hofilena,M. Shan,Carol Peña,Chetan Lathia,Ronald M. Bukowski +18 more
TL;DR: Although an OS benefit was not seen on a primary intent-to-treat analysis, results of a secondary OS analysis censoring placebo patients demonstrated a survival advantage for those receiving sorafenib, suggesting an important cross-over effect.
Journal ArticleDOI
Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma
Bernard Escudier,C. Szczylik,Thomas E. Hutson,Tomasz Demkow,Michael Staehler,Frederic Rolland,Sylvie Negrier,Nicole Beatrice Laferriere,Urban J. Scheuring,David Cella,Sonalee Shah,Ronald M. Bukowski +11 more
TL;DR: Sorafenib resulted in similar PFS as IFN-alpha-2a in patients with untreated RCC, however, sorafenIB-treated patients experienced greater rates of tumor size reduction, better QOL, and improved tolerability.
Journal ArticleDOI
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy : the SPARC trial
Cora N. Sternberg,Daniel P. Petrylak,Oliver Sartor,J. Alfred Witjes,Tomasz Demkow,Jean Marc Ferrero,Jean-Christophe Eymard,Silvia Falcon,Fabio Calabrò,Nicholas D. James,Istvan Bodrogi,Peter Harper,Manfred P. Wirth,William R. Berry,Michael E. Petrone,Thomas J. McKearn,Mojtaba Noursalehi,Martine George,Marcel Rozencweig +18 more
TL;DR: Oral satraplatin delayed progression of disease and pain in patients with metastatic CRPC experiencing progression after initial chemotherapy but did not provide a significant OS benefit.
Journal ArticleDOI
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen.
Stéphane Culine,Christine Theodore,M. De Santis,Binh Bui,Tomasz Demkow,J. Lorenz,Frederic Rolland,F.-M. Delgado,B. Longerey,Nicholas D. James +9 more
TL;DR: Vinflunine is an active agent for the treatment of platinum-pretreated bladder cancer, and these results warrant further investigation in phase III trials, either as monotherapy or in combination with other agents as treatment of advanced/metastatic TCC of the bladder.